Randomized Trialmoderate evidence
Efficacy and safety of flecainide vs amiodarone for the cardioversion of paroxysmal atrial fibrillation in patients with coronary artery disease without evidence of residual ischemia: The FLECA-ED randomized clinical trial.
Heart rhythm·October 6, 2026·PMID 42838320
Why it mattersFlecainide is traditionally contraindicated in coronary artery disease due to proarrhythmic risk, but this trial suggests it may be safe and more effective than amiodarone for acute cardioversion in selected patients without active ischemia. This could streamline emergency department management and reduce admissions.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled